Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Luminex, a provider of multiplexed solutions, and BD, a medical technology company, through its BD Diagnostics-TriPath platform, have signed a development and supply agreement. Both the companies are based in the US.
Subscribe to our email newsletter
Under the terms of the agreement, BD Diagnostics-TriPath will develop, market and sell new biomarker-based diagnostic tests for certain cancers using Luminex’s multiplexing xMAP technology platform.
BD develops technologies for cervical cancer screening, as well as diagnostic products for the detection of cancer. The company plans to expand its cancer diagnostic offerings to include a broad menu of new diagnostic tests for solid tumor cancers using Luminex’s xMAP technology.
Luminex’s xMAP Technology is a proprietary multiplexing platform that allows scientists to conduct multiple, simultaneous tests on one patient sample.
Douglas Bryant, executive vice president and COO of Luminex, said: “BD is a leader in oncology and women’s health, and we are delighted to be working with the company to advance these innovative cancer diagnostics. This agreement seeks to combine BD’s expertise and global market reach with Luminex’s industry-leading multiplexing technology to create innovative tests that will save lives.”